Our Products
A comprehensive suite of solutions to optimize your clinical trial enrollment: from performance analytics to candidate management, audience building, and study showcasing.
Tx:Perform
Get a complete view of enrollment performance across all your clinical trials, sites, and vendors in one unified platform. Identify trends and optimize recruitment strategies across your entire portfolio.
- Track enrollment across multiple studies and sites
- Connect any vendor to monitor data in real-time
- Get AI recommendations to improve performance
- Make portfolio-wide decisions with accurate forecasting
Cross-Site Performance
89%
Average enrollment rate
Vendor Analytics
5/6
Vendors meeting targets
Tx:Engage
Empower your site team to efficiently pre-screen and manage candidates with an intuitive system designed specifically for busy research staff. Spend less time on administrative tasks and more time with participants.
- Advanced pre-screening automation
- Custom recruitment analytics
- Priority support
- API access
- Team collaboration tools
Potential
4Pre-Screening
460Visit Arranged
14Enrolled
171Potential
Pre-Screening
Visit Arranged
Enrolled
Tx:YourStudyBoard
Showcase your research portfolio with a customizable study board that integrates directly with your website. Keep potential participants informed about past, present, and future study opportunities while building your recruitment pipeline.
- Highlight past, active, and future studies
- Direct channel for participant interest
- Automatic study updates from TrialConX
- Capture interested visitors for future recruitment
- Demonstrate your research portfolio
Merclinico Research
Explore our current research opportunities and find a study that interests you
Advanced Breast Cancer Treatment Study
Evaluating a novel targeted therapy for HER2-positive metastatic breast cancer.
Alzheimer's Early Detection Study
Investigating novel biomarkers for early detection of Alzheimer's disease using advanced imaging techniques.
Type 2 Diabetes Management Trial
Testing a new combination therapy approach for better glycemic control in type 2 diabetes patients.
Rheumatoid Arthritis Registry
Long-term observational study tracking treatment outcomes and disease progression in RA patients.
Advanced Breast Cancer Treatment Study
Study Overview
This phase III clinical trial is evaluating a novel targeted therapy for patients with HER2-positive metastatic breast cancer. The study aims to assess the effectiveness and safety of the investigational treatment compared to standard care.
Key Eligibility Criteria
- Age 18 years or older
- Confirmed HER2-positive metastatic breast cancer
- Previous treatment with standard therapies
- Adequate organ function
Study Duration
Treatment period: Up to 12 months
Follow-up period: Up to 2 years
Study Locations
Multiple sites across the United States and Europe
Tx:Connect
Build and nurture your own candidate database with our specialized CRM designed for clinical research organizations. Grow your recruitment capabilities while maintaining compliant communication with potential participants.
- Centralize candidate data across multiple studies
- Segment and manage different candidate lists
- Integrate with pre-screening journeys
- Enable compliant, targeted communication
- Track engagement and maintain audit trails
Total Candidates
100 +12%
New This Month
56 +8%
Unsubscribed This Month
23 +2%
Candidates
| Name | Conditions | Tags | Site | Last Contact | Actions |
|---|---|---|---|---|---|
| Sarah Chen | DepressionOCD | Medical Records | London Research Hospital | Mar 8, 2024 | |
| Michael Rodriguez | Depression | Medical Records | London Research Hospital | Feb 5, 2024 | |
| Emma Wilson | DepressionOCD | Medical Records | Birmingham Medical Institute | Feb 14, 2024 | |
| James Miller | Depression | Medical Records | London Research Hospital | Feb 11, 2024 |
Candidate History: Sarah Chen
ID: SC-2024-0892
Initial Consent Given
Aug 28, 2024
Initial platform consent
Additional Consent: depression
Sep 28, 2024
Depression study consent
Message Sent (EMAIL)
Sep 28, 2024
Initial welcome email
Pre-screener Completed: TSND-201
Oct 28, 2024
Depression study pre-screening
Clinical Screening: TSND-201
Nov 15, 2024
Initial clinical assessment